← Back to Search

68Ga-FAPI PET Scan for Cancer

Phase 2
Waitlist Available
Led By Carina A Mari, MD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights
No Placebo-Only Group

Summary

This trial studies a new imaging substance called 68Ga-FAPI that helps doctors see cancer cells more clearly in patients with various cancers. It works by attaching to cancer cells and lighting them up during a PET scan, which may help identify smaller tumors than standard imaging. Gallium-68-labeled FAPI is increasingly used in the staging of various cancers.

Eligible Conditions
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Feasibility of 68Ga-FAPI PET

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 68Ga-FAPI PET/CTExperimental Treatment3 Interventions
Patients receive 68Ga-FAPI IV and then undergo PET/CT approximately 1 hour later.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Computed Tomography (CT) scan
2017
Completed Phase 3
~180
68Ga-FAPI
2022
Completed Phase 2
~30
Positron Emission Tomography (PET) scan
2016
Completed Phase 2
~190

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,471 Previous Clinical Trials
17,501,778 Total Patients Enrolled
Carina A Mari, MDPrincipal InvestigatorStanford Universiy

Media Library

68Ga-FAPI Clinical Trial Eligibility Overview. Trial Name: NCT04023240 — Phase 2
Cancer Research Study Groups: 68Ga-FAPI PET/CT
Cancer Clinical Trial 2023: 68Ga-FAPI Highlights & Side Effects. Trial Name: NCT04023240 — Phase 2
68Ga-FAPI 2023 Treatment Timeline for Medical Study. Trial Name: NCT04023240 — Phase 2
~0 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top